Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OGESTREL 0.5/50-21 vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of norgestrel and ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; alters cervical mucus and endometrial lining.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy
Prevention of pregnancy (FDA-approved)
One tablet (norgestrel 0.5 mg / ethinyl estradiol 0.05 mg) orally once daily for 21 days, followed by 7 placebo days.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Norgestrel: 24-32 hours; Ethinyl estradiol: 7-12 hours. Clinical context: Steady state achieved after 5-7 days.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Hepatic, via CYP3A4; norgestrel undergoes reduction, conjugation; ethinyl estradiol is metabolized by CYP3A4 and undergoes glucuronidation.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal: ~50% (metabolites); Fecal/Biliary: ~50% (metabolites); <1% unchanged in urine.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Norgestrel: 93-95% to albumin and SHBG; Ethinyl estradiol: 97-98% to albumin.
~99% bound to serum albumin and sex hormone-binding globulin.
Norgestrel: 2.5-3.5 L/kg; Ethinyl estradiol: 2.5-4 L/kg. Indicates extensive tissue distribution.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: Norgestrel ~95%; Ethinyl estradiol ~40-60% due to first-pass metabolism.
Oral: ~70% due to first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment; contraindicated in severe renal disease due to potential fluid retention.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in acute or chronic hepatic disease; do not use in Child-Pugh class B or C. Use with caution in mild impairment (Child-Pugh A) at minimal effective dose.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (one tablet daily for 21 days).
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use after menopause. In elderly patients, evaluate cardiovascular and hepatic status; consider lower estrogen dose if necessary.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives; risk increases with age and heavy smoking (≥15 cigarettes/day); women over 35 who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Increased risk of thromboembolic disorders; hepatic neoplasia; elevated blood pressure; gallbladder disease; carbohydrate and lipid metabolism effects; breakthrough bleeding and spotting; use in pregnancy; depression; contact lens intolerance; fluid retention; hereditary angioedema.
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis or thromboembolic disorders; cerebrovascular or coronary artery disease; known or suspected carcinoma of the breast; carcinoma of the endometrium or other estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; pregnancy; jaundice with prior pill use; hepatic adenoma or carcinoma; age >35 and smoking ≥15 cigarettes/day.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
Grapefruit juice may inhibit CYP3A4 metabolism of ethinyl estradiol, potentially increasing estrogen exposure and risk of adverse effects. Avoid large quantities (e.g., >1 quart/day). No other significant food interactions. St. John's Wort may reduce contraceptive efficacy.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
Pregnancy category X. Contraindicated in pregnancy due to known teratogenicity. First trimester: limb defects, cardiac anomalies; second/third trimester: feminization of male fetus, urogenital abnormalities.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Excreted in breast milk; may reduce milk production and composition. M/P ratio not established. Use not recommended in nursing mothers.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
No dose adjustments as use is contraindicated during pregnancy.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
This combination oral contraceptive (COC) contains 0.5 mg norgestrel (a progestin) and 50 mcg ethinyl estradiol (a high-estrogen dose). It is a monophasic 21-day regimen. Use for contraception; also FDA-approved for moderate acne vulgaris in women >=15 years. High estrogen dose increases thrombotic risk; avoid in smokers over 35, hypertension, migraine with aura, or history of VTE. Advise consistent intake time (daily, same time). Breakthrough bleeding may occur; rule out pregnancy if missed pills. Antiepileptics (e.g., phenytoin, carbamazepine) and rifampin reduce efficacy.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill daily at the same time for 21 days, then 7 days off; withdrawal bleeding occurs during the 7-day break.,Use backup contraception (e.g., condoms) if you miss a pill, vomit within 2 hours of taking it, or have severe diarrhea.,This pill does not protect against HIV or other sexually transmitted infections.,Serious side effects: leg pain (DVT), chest pain (PE), severe headache (stroke), jaundice (liver disease); stop and call doctor immediately.,Do not smoke while taking this pill, especially if over 35; smoking greatly increases risk of blood clots.,Tell your doctor if you are breastfeeding, planning pregnancy, or have any medical conditions (e.g., hypertension, diabetes, migraine).,Grapefruit juice may increase estrogen levels; avoid excessive consumption.,Antibiotics (e.g., rifampin) and certain anticonvulsants can reduce effectiveness.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OGESTREL 0.5/50-21 vs AFIRMELLE, answered by our medical review team.
OGESTREL 0.5/50-21 is a Oral Contraceptive that works by Combination of norgestrel and ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; alters cervical mucus and endometrial lining.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OGESTREL 0.5/50-21 and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OGESTREL 0.5/50-21 is: One tablet (norgestrel 0.5 mg / ethinyl estradiol 0.05 mg) orally once daily for 21 days, followed by 7 placebo days.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OGESTREL 0.5/50-21 and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OGESTREL 0.5/50-21 is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to known teratogenicity. First trimester: limb defects, cardiac anomalies; second/third trimester: feminization of male fetus. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.